Trial reportGut2024
Compared to histamine-2 receptor antagonist, proton pump inhibitor induces stronger oral-to-gut microbial transmission and gut microbiome alterations: a randomised controlled trial.
Trial report in Gut, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07791849 (Comparative Effect of Proton Pump Inhibitors and Gastric Mucosal Protective Agents on Acute Graft-versus-Host Disease Post-Transplantation), which is not on this map. Cited by 56 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Effect of Proton Pump Inhibitors and Gastric Mucosal Protective Agents on Acute Graft-versus-Host Disease Post-Transplantation: A Prospective Randomized Controlled Trial
Who cites it
56 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The Oral-Gut Microbiome Connection in Patients with Periodontitis: A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Gastrointestinal microbiota alterations associated with pediatric gastroesophageal reflux disease and proton pump inhibitor exposure: a systematic review of microbiome changes, dysbiosis markers, and associated clinical outcomes.Frontiers in nutrition · 2026Pooled it
- Proton pump inhibitors and risk of hearing loss; a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- Proton pump inhibitors and the risk of gastric cancer: a systematic review, evidence synthesis and life course epidemiology perspective.BMJ open gastroenterology · 2025Pooled it
- Hewei Jiangni recipe improved the quality of life in patients with cold-heat mixed nonerosive reflux disease: a randomized, double-blinded study.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Trial
- Lactic acid bacteria and endogenous ethanol mediate proton pump inhibitor-associated MASLD: a multicohort cross-sectional mediation analysis.Gut microbes · 2026Article
- Microbes and medicines: interrelationships between pharmaceuticals and the gut microbiome.Gut microbes · 2026Review
- Dietary modulation of the gut microbiota in type 2 diabetes and obesity: mechanisms, interventions, and clinical perspectives.Acta diabetologica · 2026Review
- Identifying low-quality features and suboptimal models to enhance phenotype prediction.Patterns (New York, N.Y.) · 2026Article
- Peritonitis and Mortality Risks of Gastric Acid Suppressants in Patients Undergoing Peritoneal Dialysis.Kidney international reports · 2026Article
- Gastric Acid Suppression in Peritoneal Dialysis: An Old Question Revisited With a New Study Design.Kidney international reports · 2026Article
- Sustained proton-pump inhibitor exposure and incident age-related macular degeneration: a new-user, population-based cohort study.BMJ open ophthalmology · 2026Observational
- Active and Non-Active Comparators Yield Different Estimates of the Association Between Proton Pump Inhibitor Use and Recorded Mortality During Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.Pharmacoepidemiology and drug safety · 2026Article
- Beyond the Lungs: ICU Oral Care and Gut Resilience-A Hypothesis-Generating Narrative Review.Microorganisms · 2026Review
- Pharmacovigilance Analysis of Drug-Induced Stomatitis: Insights From Twenty-One Years of Real-World Data.International dental journal · 2026Article
- Association between prenatal exposure to acid-suppressive medications and subsequent risk of autoimmune diseases in offspring: a nationwide birth cohort study in South Korea.World journal of pediatrics : WJP · 2026Article
- Use of Antihistamine Drugs in Colitis: A Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Gut microbiota and aging: current understanding and future perspectives.Molecular biomedicine · 2026Review
- Chronic proton pump inhibitor exposure aggravates intestinal injury by impairing intestinal stem cell self-renewal through the microbiota-7-ketolithocholic acid Axis.Journal of translational medicine · 2026Article
- Initiation of proton pump inhibitors is associated with gut microbiome diversity and composition: a new-user target trial emulation within the Baltimore Longitudinal Study of Aging.American journal of epidemiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aim to compare the effects of proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) on the gut microbiota through longitudinal analysis.
designHealthy volunteers were randomly assigned to receive either PPI (n=23) or H2RA (n=26) daily for seven consecutive days. We collected oral (saliva) and faecal samples before and after the intervention for metagenomic next-generation sequencing. We analysed intervention-induced alterations in the oral and gut microbiome including microbial abundance and growth rates, oral-to-gut transmissions, and compared differences between the PPI and H2RA groups.
resultsBoth interventions disrupted the gut microbiota, with PPIs demonstrating more pronounced effects. PPI usage led to a significantly higher extent of oral-to-gut transmission and promoted the growth of specific oral microbes in the gut. This led to a significant increase in both the number and total abundance of oral species present in the gut, including the identification of known disease-associated species like
conclusionOur study provides evidence that PPIs have a greater impact on the gut microbiome and oral-to-gut transmission than H2RAs, shedding light on the mechanism underlying the higher risk of certain diseases associated with prolonged PPI use. TRIAL REGISTRATION NUMBER: ChiCTR2300072310.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.